165 related articles for article (PubMed ID: 7339332)
21. Cholinesterase inhibitors in myasthenia gravis.
Lange MJ
Practitioner; 1966 Mar; 196(173):448-53. PubMed ID: 5905423
[No Abstract] [Full Text] [Related]
22. Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis.
Milner-Brown HS; Mellenthin M; Sharma ML; Miller RG
Neurology; 1987 May; 37(5):800-3. PubMed ID: 3574680
[TBL] [Abstract][Full Text] [Related]
23. [Blood cholinesterase during the treatment of myasthenia by anti-cholinesterase drugs (prostigmine and mestinon)].
VINCENT D; PLANQUES J; GERAUD J; DARDENNE P
Therapie; 1960; 15():906-13. PubMed ID: 13781449
[No Abstract] [Full Text] [Related]
24. A radioimmunoassay for pyridostigmine.
Meyer HG; Lukey BJ; Gepp RT; Corpuz RP; Lieske CN
J Pharmacol Exp Ther; 1988 Nov; 247(2):432-8. PubMed ID: 3183945
[TBL] [Abstract][Full Text] [Related]
25. Continuous infusion of pyridostigmine for myasthenic crisis.
Nicholson J; Grant IS
Crit Care Med; 1994 May; 22(5):895-6. PubMed ID: 8181302
[No Abstract] [Full Text] [Related]
26. A modified gas-liquid chromatographic assay to monitor plasma mexiletine in a tinnitus study.
Pilling M; Tse J; Chan K
Methods Find Exp Clin Pharmacol; 1982; 4(4):243-7. PubMed ID: 7121133
[TBL] [Abstract][Full Text] [Related]
27. MANAGEMENT OF MYASTHENIA GRAVIS IN THE OBSTETRICAL PATIENT.
MCNALL PG; JAFARNIA MR
Am J Obstet Gynecol; 1965 Jun; 92():518-25. PubMed ID: 14295887
[No Abstract] [Full Text] [Related]
28. Method for isolation and determination of pyridostigmine and metabolites in urine and blood.
Ellin RI; Zvirblis P; Wilson MR
J Chromatogr; 1982 Mar; 228():235-44. PubMed ID: 7076747
[TBL] [Abstract][Full Text] [Related]
29. Treatment of myasthenia. II.
Br Med J; 1971 Apr; 2(5755):213-4. PubMed ID: 5575956
[No Abstract] [Full Text] [Related]
30. Effect of neostigmine and pyridostigmine on the plasma cholinesterase activity.
Baraka A; Wakid N; Mansour R; Haddad W
Br J Anaesth; 1981 Aug; 53(8):849-51. PubMed ID: 7272149
[TBL] [Abstract][Full Text] [Related]
31. Steady state kinetics of pyridostigmine in myasthenia gravis.
Sørensen PS; Flachs H; Friis ML; Hvidberg EF; Paulson OB
Neurology; 1984 Aug; 34(8):1020-4. PubMed ID: 6540381
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and oral bioavailability of pyridostigmine in man.
Aquilonius SM; Eckernäs SA; Hartvig P; Lindström B; Osterman PO
Eur J Clin Pharmacol; 1980 Nov; 18(5):423-8. PubMed ID: 7439266
[TBL] [Abstract][Full Text] [Related]
33. Chromatographic method for the determination of diazepam, pyridostigmine bromide, and their metabolites in rat plasma and urine.
Abu-Qare AW; Abou-Donia MB
J Chromatogr B Biomed Sci Appl; 2001 Apr; 754(2):503-9. PubMed ID: 11339294
[TBL] [Abstract][Full Text] [Related]
34. Adverse interaction between corticosteroid hormones and anticholinesterase drugs.
Patten BM; Oliver KL; Engel WK
Trans Am Neurol Assoc; 1973; 98():248-52. PubMed ID: 4784943
[No Abstract] [Full Text] [Related]
35. Administering Neostigmine as a Subcutaneous Infusion: A Case Report of a Patient Dying With Myasthenia Gravis.
Hindmarsh J; Woods E; Lee M; Pickard J
J Palliat Care; 2020 Apr; 35(2):78-81. PubMed ID: 31411109
[TBL] [Abstract][Full Text] [Related]
36. Determination of neostigmine in human plasma and cerebrospinal fluid by high-performance liquid chromatography with ultraviolet detection.
Varin F; Couture J; Gao H
J Chromatogr B Biomed Sci Appl; 1999 Feb; 723(1-2):319-23. PubMed ID: 10080662
[TBL] [Abstract][Full Text] [Related]
37. Plasma concentration and pharmacological effects of pyridostigmine in patients with myasthenia gravis [proceedings].
Calvey TN; Chan K
Br J Clin Pharmacol; 1977 Jun; 4(3):404P. PubMed ID: 197984
[No Abstract] [Full Text] [Related]
38. Plasma pyridostigmine levels in myasthenia gravis.
White MC; De Silva P; Havard CW
Neurology; 1981 Feb; 31(2):145-50. PubMed ID: 7193298
[TBL] [Abstract][Full Text] [Related]
39. Pyridostigmine levels in myasthenia gravis.
Kornfeld P; Mittag T; Genkins G; Papatestas AE; Horowitz SH
Neurology; 1977 Nov; 27(11):1099. PubMed ID: 563008
[No Abstract] [Full Text] [Related]
40. The effect of chronic pyridostigmine administration on pyridostigmine-14C metabolism in myasthenia gravis.
Kornfeld P; Wolf RL; Samuels AJ; Osserman KE
Neurology; 1971 May; 21(5):550-2. PubMed ID: 5104099
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
